Shailender Bhatia, MD, on Merkel Cell Carcinoma: Final Results of a Phase II Study
2015 European Cancer Congress
Shailender Bhatia, MD, of the Fred Hutchinson Cancer Center, discusses his paper on interleukin-12 DNA and regression of Merkel cell tumors (Abstract 504).
Matteo Lambertini, MD
Matteo Lambertini, MD, Dana-Farber Cancer Institute, discusses the use of LHRH agonists during chemotherapy to suppress ovarian function as a way to preserve fertility in breast cancer patients (Abstract 1957).
Toni K. Choueiri, MD
Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses results of the phase III METEOR trial in advanced renal cell carcinoma, which evaluated the efficacy of cabozantinib compared to everolimus in patients with disease progression after VEGFR-targeted therapy (Abstract 4LBA).
Jean-Charles Soria, MD, PhD
Jean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: afatinib vs erlotinib in squamous cell carcinoma of the lung.
Clifford A. Hudis, MD
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, summarizes his educational lecture on obesity, inflammation, and cancer—an important topic in oncology.
Jean-Charles Soria, MD, PhD
Jean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: the efficacy and safety of pembrolizumab in previously treated non-small cell lung cancer (Abstract LBA33).